Intersect Capital LLC grew its holdings in Merck & Company, Inc. (NYSE:MRK) by 41.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,808 shares of the company’s stock after buying an additional 17,729 shares during the period. Merck & accounts for about 2.3% of Intersect Capital LLC’s holdings, making the stock its 12th biggest holding. Intersect Capital LLC’s holdings in Merck & were worth $3,897,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Stelac Advisory Services LLC acquired a new stake in shares of Merck & in the second quarter valued at about $104,000. Perennial Advisors LLC raised its position in shares of Merck & by 10.7% in the second quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after buying an additional 157 shares during the last quarter. Cascade Investment Advisors Inc. raised its position in shares of Merck & by 15.5% in the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after buying an additional 232 shares during the last quarter. Vigilant Capital Management LLC raised its position in shares of Merck & by 16.7% in the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after buying an additional 250 shares during the last quarter. Finally, Solaris Asset Management LLC raised its position in shares of Merck & by 6.3% in the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after buying an additional 115 shares during the last quarter. Institutional investors and hedge funds own 73.15% of the company’s stock.

Merck & Company, Inc. (MRK) opened at $55.10 on Tuesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.16 and a current ratio of 1.43. The firm has a market cap of $151,151.77, a PE ratio of 14.26, a price-to-earnings-growth ratio of 2.39 and a beta of 0.78. Merck & Company, Inc. has a 12 month low of $54.41 and a 12 month high of $66.80.

Merck & (NYSE:MRK) last announced its earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.08. The company had revenue of $10.33 billion during the quarter, compared to analyst estimates of $10.54 billion. Merck & had a net margin of 11.60% and a return on equity of 27.08%. Merck &’s revenue was down 2.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.07 earnings per share. equities analysts forecast that Merck & Company, Inc. will post 3.95 EPS for the current year.

In other news, Director Thomas H. Glocer sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total value of $281,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.25% of the company’s stock.

A number of brokerages have recently commented on MRK. HSBC Holdings plc upgraded shares of Merck & from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 9th. Cowen and Company reiterated a “hold” rating and issued a $70.00 target price on shares of Merck & in a research report on Friday, November 3rd. BidaskClub cut shares of Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. UBS AG reduced their target price on shares of Merck & from $72.00 to $67.00 and set a “buy” rating for the company in a research report on Monday, October 30th. Finally, Barclays PLC cut shares of Merck & from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $72.00 to $62.00 in a research report on Monday, October 30th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. Merck & has an average rating of “Hold” and an average target price of $67.07.

TRADEMARK VIOLATION WARNING: “Intersect Capital LLC Acquires 17,729 Shares of Merck & Company, Inc. (MRK)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/intersect-capital-llc-acquires-17729-shares-of-merck-company-inc-mrk/1701534.html.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.